Includes the design and development of a cost-effective process to deliver high yield and productivity
EMD Millipore, the life science business of Merck KGaA of Darmstadt, Germany will provide upstream process development services for Precision Biologics, a Texas, US-based clinical-stage biotechnology company, to advance a preclinical monoclonal antibody. The antibody, NEO-201, binds to a tumour-specific antigen found in several forms of cancer, offering therapeutic potential across multiple cancer types, including colorectal, lung, ovarian, and pancreatic.
Under the agreement, Billerica, MA-based EMD Millipore, known as Merck Millipore outside the US and Canada, will provide process development through its Provantage Services offering, which leverages the company's expertise in biopharmaceutical manufacturing to help customers design and develop processes that improve yield and productivity while reducing costs and accelerating time to market. The process development will take place at EMD Millipore's single-use GMP biodevelopment centre in Martillac, France.
'We chose to partner with EMD Millipore because of its legacy of scientific and process development expertise,' said Philip Arlen, President and Chief Executive of Precision Biologics. 'We are confident that EMD Millipore will be a valuable partner in advancing NEO-201 and helping to bring a potential new therapeutic to patients in need.'